权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Biomarker of Lung Disease in African Americans

非裔美国人肺部疾病的生物标志物

基本信息

批准号：
9755496
负责人：
RUSSELL Paul BOWLER
金额：
$ 80.59万
依托单位：
NATIONAL JEWISH HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-08-15 至 2022-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9755496
关键词：
Address Admixture Advanced Glycosylation End Products African African American Asians Biological Markers Blood Cause of Death Chronic Chronic Obstructive Airway Disease Clinical Clinical Trials Collaborations Data Diagnostic tests Disease Disease Pathway Disease Progression Distal Early treatment European FDA approved Fibrinogen Functional Imaging Funding Gene Proteins Genetic Genomics Goals Knowledge Latino Lead Longitudinal cohort Lung Lung diseases Messenger RNA MicroRNAs Minority Molecular Molecular Profiling National Heart, Lung, and Blood Institute Not Hispanic or Latino Participant Pathogenesis Pathway interactions Patients Phenotype Plasma Population Population Attributable Risks Precision Health Prevention Proteins Proteomics Publications Pulmonary Emphysema Research Personnel Respiratory physiology Risk Risk Factors Severities Severity of illness Smoker Smoking Testing United States United States National Institutes of Health Whole Blood airway obstruction base biobank cohort cost disease phenotype disorder risk genetic variant genome sequencing health disparity high risk improved molecular subtypes novel novel diagnostics novel marker outcome forecast precision medicine protein expression protein protein interaction proteomic signature racial difference receptor smoking-related lung disease transcriptome sequencing transcriptomics treatment strategy virtual whole genome

项目摘要

PROJECT SUMMARY/ABSTRACT Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death in the US1,2. Although COPD occurs predominantly in smokers, it is unknown why only a minority of smokers (~20-40%) develops chronic airflow limitation or destruction of distal airspaces (emphysema). Identification molecular profiles from current or former smokers who are likely to progress is a crucial step in understanding the pathogenesis of COPD and emphysema. There are very few publications that describe COPD biomarkers in large, well phenotyped cohorts that include a significant number of African Americans. This study will leverage large NIH- supported cohorts (COPDGene, SPIROMICS, and MESA-Lung) that have large number of well-characterized African Americans subjects with or at risk for COPD. Since the subjects have stored plasma and have been followed for 7-10 years with extensive clinical, physiologic, and imaging, we can very cost-effectively apply a proteomic approach. Furthermore, because the cohorts have other valuable Omics data, we can integrate the proteomic findings with whole genome sequencing and other advanced molecular studies such as genomics. This knowledge may help develop novel diagnostic tests and therapies for early prevention and treatment of COPD and will identify any markers that are specific to smoking-related lung disease in African Americans.

项目总结/文摘